Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Apremilast and Methotrexate monotherapy on Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Trial Profile

Study of Apremilast and Methotrexate monotherapy on Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apremilast (Primary) ; Disease-modifying antirheumatics; Hydroxychloroquine; Leflunomide; Methotrexate; Sulfasalazine; Tofacitinib
  • Indications Psoriatic arthritis; Spondylarthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Apr 2021 Results comparing patient characteristics and disease burden between men and women with axial spondyloarthritis, published in The Journal of Rheumatology
    • 15 Nov 2020 Results (n=150) of exploratory analysis evaluating whether apremilast monotherapy is an effective treatment option for oligoarticular PsA, published in The Journal of Rheumatology
    • 06 Jun 2020 Results (N=119), assessing trends in characteristics of patients starting apremilast from 2014-2019 and compare characteristics of treatment naive patients, presented at the 21st Annual Congress of the European League Against Rheumatism
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top